First approved in the treatment of advanced melanoma, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors either alone or in combination are now widely utilized in a variety of tumors [1–3]. Here, PDCD1 is linked to melanoma.